Last updated: February 15, 2026
Overview
NDC 00093-1712 is a medication manufactured by Novartis Pharmaceuticals Corporation, predominantly used to treat multiple sclerosis (MS). The drug, Gilenya (fingolimod), received FDA approval in 2010. As a first-dose oral sphingosine 1-phosphate receptor modulator, it revolutionized MS treatment by offering an oral alternative to injectables.
Market Size and Demand
The global multiple sclerosis treatment market is valued at approximately $23 billion in 2022. The U.S. accounts for about 50% of this market, roughly $11.5 billion. Gilenya’s share of the MS oral therapy segment is estimated at approximately 25-30%.
- U.S. MS population: 1 million diagnosed
- Treatment-naïve patients: 600,000
- Patients on disease-modifying therapies (DMTs): 75% (450,000)
Gilenya’s current market penetration is approximately 20% of oral DMTs, equating to 90,000 patients.
Pricing and Revenue Estimates
Gilenya’s wholesale acquisition cost (WAC) is roughly $6,647 per month per patient, translating to about $79,764 annually. Contracted prices (net prices) are often 30-50% lower due to rebates and discounts.
- Estimated net price per patient/year: $40,000 - $55,000
- Current annual revenue estimate (U.S.): $360 million (based on 90,000 patients at $4,000/month average net price)
International markets, especially in Europe (EU), have similar pricing adjusted for local reimbursement policies, adding substantial revenue overseas.
Market Competition
Gilenya faces competition mainly from other oral MS therapies such as:
- Tecfidera (dimethyl fumarate): projected global sales surpassing $4 billion in 2022.
- Jelenya (daclizumab): phased out due to safety concerns.
- Mayzent (siponimod): approved in 2019, gaining market share.
- Zeposia (ozanimod): approved in 2020, expanding oral options.
Injectable therapies like Rebif and Avonex still hold market segments, but oral drugs increasingly dominate due to convenience.
Price Trajectory and Future Projections
-
Short-term (2023-2025): Prices are expected to stabilize or decline marginally due to increased competition. Discounting trends and patient access programs will pressure net prices downward by 10-15%. Revenue growth will primarily originate from increased patient adoption.
-
Mid-term (2025-2030): Patent exclusivity is set to expire by around 2028, unless patent extensions occur. Generic or biosimilar versions could reduce prices by 30-50%, causing revenue declines. Market share could shift toward newer therapies with favorable safety profiles.
-
Long-term (beyond 2030): Innovations in MS treatments, including oral drugs with improved safety and efficacy, might erode Gilenya’s dominance. Market shifts depend on regulatory approvals, clinical trial outcomes, and reimbursement policies.
Regulatory and Pricing Policies
In the U.S., the Inflation Reduction Act of 2022 targets drug pricing reforms, including Medicare negotiations and price caps for some drugs. These could pressure Gilenya prices in governmental programs, influencing commercial prices as well.
In Europe, pricing is negotiated by health authorities, with discounts often achieved through confidential rebate agreements. Entry of generics would necessitate market adjustments.
Key Price Drivers
- Patent expiration timelines and potential generic entry (expected in 2028).
- Competitive developments among other oral DMTs.
- Reimbursement policies affecting net pricing.
- Clinical trial results influencing physician prescribing.
Summary
Gilenya remains a substantial revenue generator within MS treatments but faces upcoming price and market share pressures. Short-term prospects show stable or slightly declining prices with incremental growth driven by broader adoption. Long-term outlook suggests potential revenue erosion following patent expiry and increased generic competition.
Key Takeaways
- Current US revenue: ~$360 million annually from an estimated 90,000 patients.
- Average net price: $40,000–$55,000 per patient per year.
- Patent expiry: Around 2028, risking significant price reductions.
- Market position: Leading MS oral therapy, but competing with newer drugs.
- Future trends: Price decreases due to generics, evolving competitive landscape, regulatory impacts.
FAQs
Q1: What is the primary revenue driver for Gilenya?
Patient retention and increased market penetration within the MS oral therapy segment.
Q2: How soon could generic versions of Gilenya enter the market?
Likely around 2028, following patent expiration.
Q3: What factors could impact Gilenya’s market share?
Emergence of new therapies with better safety profiles, patent expiry, and pricing policies.
Q4: How are international prices adjusted?
Via negotiated rebates and local reimbursement policies, often resulting in lower net prices than in the U.S.
Q5: What will be the impact of upcoming regulations on Gilenya’s pricing?
Potential price caps and negotiation policies could reduce net revenues in Medicare and other programs.
References
- IQVIA, "Global MS Treatment Market Analysis," 2022.
- Novartis Annual Report, 2022.
- U.S. FDA, Gilenya Approval Document, 2010.
- Industry Price Data, Medicaid Drug Pricing & USPPI, 2022.
- Congressional Budget Office, "Potential Impact of Medicare Negotiation Policies," 2022.
